POZEN Reports Superior Platelet Inhibition of PA32540 Regimen Over a Standard of Care Regimen in a Phase 1 Study

POZEN Inc. POZN announced today positive top-line results of a Phase 1 study of PA32540, a novel coordinated-delivery tablet of enteric-coated aspirin (325 mg) and immediate-release omeprazole (40 mg). The data from the Co-Rx Study suggest that PA32540 given in conjunction with clopidogrel, dosed at least 10 hours apart, resulted in significantly better inhibition of ADP-induced platelet aggregation (anti-clotting) when compared to a current standard of care (81 mg of EC aspirin, EC omeprazole 40 mg and clopidogrel). Additional data from this study are expected to be presented at an upcoming scientific meeting.